Evidence map›Paper›PMID 25470057›Full record

ArticleNature2015

Interception of host angiogenic signalling limits mycobacterial growth.

Stefan H Oehlers, Mark R Cronan, Ninecia R Scott, Monica I Thomas, Kazuhide S Okuda, Eric M Walton, Rebecca W Beerman, Philip S Crosier, David M Tobin

Abstract read
In one paragraph

Article in Nature, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 155 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
155citing papers in PubMed, 1 pooled it
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

155 citing papers in PubMed, 1 synthesis or guideline pooled it, 274 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. P-body-mediated RNA decay controls neural crest EMT.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  6. Polyketide synthase 12 is anbioRxiv : the preprint server for biology · 2026
    Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Pathogens (Basel, Switzerland) · 2025
    Review
  18. A granulin-positive macrophage subtype in mycobacterial granulomas alleviates tissue damage by limiting excessive inflammation.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  19. Review
  20. Review

95 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Stefan H OehlersDepartment of Molecular Genetics and Microbiology, Center for Microbial Pathogenesis, Duke University Medical Center, Durham, North Carolina 27710, USA.
Mark R CronanDepartment of Molecular Genetics and Microbiology, Center for Microbial Pathogenesis, Duke University Medical Center, Durham, North Carolina 27710, USA.
Ninecia R ScottDepartment of Molecular Genetics and Microbiology, Center for Microbial Pathogenesis, Duke University Medical Center, Durham, North Carolina 27710, USA.
Monica I ThomasDepartment of Molecular Genetics and Microbiology, Center for Microbial Pathogenesis, Duke University Medical Center, Durham, North Carolina 27710, USA.
Kazuhide S OkudaDepartment of Molecular Medicine and Pathology, The University of Auckland, Auckland 1023, New Zealand.
Eric M WaltonDepartment of Molecular Genetics and Microbiology, Center for Microbial Pathogenesis, Duke University Medical Center, Durham, North Carolina 27710, USA.
Rebecca W BeermanDepartment of Molecular Genetics and Microbiology, Center for Microbial Pathogenesis, Duke University Medical Center, Durham, North Carolina 27710, USA.
Philip S CrosierDepartment of Molecular Medicine and Pathology, The University of Auckland, Auckland 1023, New Zealand.
David M TobinDepartment of Molecular Genetics and Microbiology, Center for Microbial Pathogenesis, Duke University Medical Center, Durham, North Carolina 27710, USA.
Duke University Hospital · USDuke Medical Center · USUniversity of Auckland · NZ

Funding

Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI Susanna Naggie, GEORGIA Doris TOMARAS · 2005 to 2026
$50.5M
ORGANIZATION AND FUNCTIONS OF CELLULAR STRUCTUREST32GM007184 · NIGMS · DUKE UNIVERSITY · PI JINKS-ROBERTSON, SUE · 1985 to 2019
$18.2M
Modulating Eicosanoids to Treat Tuberculosis: Personalized, Host-directed TherapyDP2OD008614 · OD · DUKE UNIVERSITY · PI TOBIN, DAVID M. · 2011 to 2011
$2.4M
NIAID NIH HHS 5P30 AI064518NIAID NIH HHS P30 AI064518NIGMS NIH HHS T32 GM007184NIH HHS 1DP2-OD008614NIH HHS DP2 OD008614
6 · The paper itself

Abstract

Pathogenic mycobacteria induce the formation of complex cellular aggregates called granulomas that are the hallmark of tuberculosis. Here we examine the development and consequences of vascularization of the tuberculous granuloma in the zebrafish-Mycobacterium marinum infection model, which is characterized by organized granulomas with necrotic cores that bear striking resemblance to those of human tuberculosis. Using intravital microscopy in the transparent larval zebrafish, we show that granuloma formation is intimately associated with angiogenesis. The initiation of angiogenesis in turn coincides with the generation of local hypoxia and transcriptional induction of the canonical pro-angiogenic molecule Vegfaa. Pharmacological inhibition of the Vegf pathway suppresses granuloma-associated angiogenesis, reduces infection burden and limits dissemination. Moreover, anti-angiogenic therapies synergize with the first-line anti-tubercular antibiotic rifampicin, as well as with the antibiotic metronidazole, which targets hypoxic bacterial populations. Our data indicate that mycobacteria induce granuloma-associated angiogenesis, which promotes mycobacterial growth and increases spread of infection to new tissue sites. We propose the use of anti-angiogenic agents, now being used in cancer regimens, as a host-targeting tuberculosis therapy, particularly in extensively drug-resistant disease for which current antibiotic regimens are largely ineffective.

Indexed as

Angiogenesis InhibitorsAnimalsAntibiotics, AntitubercularBacterial LoadDisease Models, AnimalDrug SynergismGranulomaHypoxiaLarvaMacrophagesMycobacterium Infections, NontuberculousMycobacterium marinumNeovascularization, PathologicReceptors, Vascular Endothelial Growth FactorSignal TransductionTuberculosisAngiogenesis InhibitorsAntibiotics, AntitubercularReceptors, Vascular Endothelial Growth FactorVascular Endothelial Growth Factor A

Identifiers

PMID25470057
PMCPMC4312197
OpenAlexW2104048810

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.